A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Studied

Randomized trial comparing liraglutide with placebo for weight loss, with lifestyle counseling in both groups.

Who / model

3731 adults without type 2 diabetes, with obesity or overweight plus abnormal blood lipids or hypertension; treatment lasted 56 weeks.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

All primary weight outcomes favored liraglutide: average loss was 8.4 versus 2.8 kg; 63.2% versus 27.1% lost at least 5%, and 33.1% versus 10.6% lost more than 10%. Mild or moderate nausea and diarrhea were common. Serious events occurred in 6.2% versus 5.0%.

Limits

The reported weight analysis filled missing values by carrying forward the last recorded observation.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary